NLRP3 inflammasome contributes to the development of a wide variety of human diseases, including gout, atherosclerosis, neurodegenerative diseases and type 2 diabetes (T2D), but the medications targeting NLRP3 inflammasome are not available in clinic. This evidence concerns the gene NLRP3 and type 2 diabetes mellitus.